Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SD9V
|
|||
| Former ID |
DNCL001690
|
|||
| Drug Name |
Flupirtine
|
|||
| Synonyms |
Flupirtine; 56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Phase 2 | [1], [2] | |
| Fibromyalgia [ICD-11: MG30.01; ICD-10: M79.7] | Phase 2 | [1], [2] | ||
| Company |
Adeona Pharmaceuticals; MI Meda Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H17FN4O2
|
|||
| Canonical SMILES |
CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N
|
|||
| InChI |
1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)
|
|||
| InChIKey |
JUUFBMODXQKSTD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 56995-20-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7814906, 8183006, 11111201, 14800640, 34717383, 47647593, 50064925, 50111073, 57313508, 77915713, 90341043, 93299608, 96024673, 103555997, 104301761, 124749800, 124880148, 124880149, 126658653, 126686248, 128330548, 134224990, 135047758, 135650276, 137005700, 137255514, 139028353, 162187716, 164193606, 174006272, 175427080, 179150677, 196105444, 198976803, 210275567, 210281215, 223398980, 223674379, 224336873, 226413200, 241376151, 250133628, 252156847, 252657738
|
|||
| ChEBI ID |
CHEBI:94646
|
|||
| SuperDrug ATC ID |
N02BG07
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated potassium channel Kv7 (KCNQ) | Target Info | Modulator | [3] |
| KEGG Pathway | Adrenergic signaling in cardiomyocytes | |||
| Cholinergic synapse | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Protein digestion and absorption | ||||
| Vibrio cholerae infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2598). | |||
| REF 2 | ClinicalTrials.gov (NCT00623415) Flupirtine as Oral Treatment in Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 3 | Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.